AMGN vs SMMT · P/E 24, rev $10.05B vs $11.46B cap
Amgen Inc (AMGN) versus Summit Therapeutics PLC (SMMT) — a side-by-side from cached financials, not a winner call.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Summit Therapeutics PLC (SMMT) is a biotechnology company listed on US.
Latest reported AMGN revenue for 2026-06-30 was $10.05B. Net income was $2.38B. Revenue was up 16.7% from 2026-03-31 to 2026-06-30. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
SMMT does not have a complete income-statement cache yet.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. SMMT currently screens at market cap $11.46B.
Not investment advice. Open the AMGN and SMMT stock pages for the full models.
Not investment advice.